



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/006,867	12/06/2001	Dan L. Eaton	P3230R1C1	6830

30313 7590 09/04/2003

KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER

HELMS, LARRY RONALD

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 09/04/2003

17

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/006,867

Applicant(s)

EATON ET AL.

Examiner

Larry R. Helms

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 39-51 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 39-51 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 10.
- 4) ☐ Interview Summary (PTO-413) Paper No(s) ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

DETAILED ACTION

1. Claims 1-38 have been canceled.
Claims 39-51 have been added.
2. Claims 39-51 are pending and under examination.

Specification

3. The amendment filed 1/8/02 and 7/16/02 are objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: the amendments filed 1/8/02 and 7/16/02 update the continuation data by adding provisional and PCT applications and incorporates the applications by reference which is not permitted after filing the application (see 35 USC 132(a) and Dart industries v. Banner, 636 F.2d 684,207 USPQ 273 (CAFC 1980)).

Applicant is required to cancel the new matter in the reply to this Office Action.

Claim Rejections - 35 USC § 101

4. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

5. Claims 39-51 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a substantial asserted utility or a well established utility.

Claims 39-51 are directed to isolated polypeptides that are 80-100% identical to SEQ ID NO:2 or full length or extracellular domain or sequences lacking the signal sequence as well as polypeptide encoded by the full-length of the cDNA deposited under ATCC 203099 and fusion proteins comprising such. The specification discloses the isolation of a nucleic acid, SEQ ID NO:1, which encodes a protein, SEQ ID NO:2 which is disclosed as PRO 180 (see page 6). The polynucleotide is disclosed to be more highly expressed in rectum tumor than normal rectum (see page 93), however, the specification does not disclose that the polypeptide is over expressed in tumor vs. normal. Thus, the specification asserts that the pro polypeptide encoding nucleic acid being expressed in tumor vs. normal equates to the use of the molecule for diagnosis as well as a therapeutic target (see page 93). There is no supporting evidence that the polypeptide is overexpressed in tumor tissue and as such one skill in the art would conclude that the polypeptide is not supported by a substantial asserted utility or a well established utility. In addition, the specification does not disclose any polypeptide that is at least 80-99% identical to SEQ ID NO:2 that is over expressed in tumor vs. normal tissue and as such these polypeptides are not supported by a substantial asserted utility or a well established utility. The specification does not disclose a correlation between any specific disorder and an altered level or form of the claimed polypeptides. Also, the specification does not predict whether the claimed polypeptides would be

overexpressed or underexpressed in a specific, diseased tissue compared to the healthy tissue control.

The instant application has failed to provide guidance as to how one of skill in the art could use the claimed invention in a way that constitutes a substantial utility. The proposed uses of the claimed invention are simply starting points for further research and investigation into potential practical uses of the claimed polypeptides. "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing." *Brenner v. Manson*, 148 USPQ at 696.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 39-51 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

8. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1642

9. Claims 39-51 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

a. Claims 39-51 are indefinite because the protein identified as PRO180 is a soluble protein, and is not disclosed as being expressed on a cell surface. Accordingly, the limitation that the claimed protein comprises an "extracellular domain" (for example see claim 39 parts (c) and (d)) is indefinite, as the art does not recognize soluble proteins as having such domains. Further, if the protein had an extracellular domain, the recitation of "the extracellular domain"..."lacking its associated signal sequence" (claim 39, part (d), for example) is indefinite as a signal sequence is not generally considered to be part of an extracellular domain, as signal sequences are cleaved from said domains in the process of secretion from the cell.

b. Claim 51 is indefinite for reciting "epitope tag" because the exact meaning of the phrase is not clear. Does the phrase mean an "epitope" where an antibody binds or a tag that allows for purification that is an amino acid sequence that does not require binding to an antibody, or some other tag?

10. Claims 39-43, and 50 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to polypeptides having at least 80%, 85%, 90%, 95% or 99% sequence identity with a particular disclosed sequence. The claims do not require that the polypeptide possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. Thus, the claims are drawn to a genus of polypeptides that is defined only by sequence identity.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity. There is not even identification of any particular portion of the structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the

encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only isolated polypeptides comprising the sequence set forth in SEQ ID NO: 2, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

11. Claims 39-44, 49-51 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention and failing to provide an

Art Unit: 1642

enabling disclosure without complete evidence either that the claimed biological materials are known and readily available to the public or complete evidence of the deposit of the biological materials.

The specification lacks complete deposit information for the deposit of the cell line containing cDNA deposited under ATCC accession No. 203099. It is not clear that the cDNA deposited as ATCC no. 203099 is known and publicly available or can be reproducibly isolated from nature without undue experimentation or is the same as SEQ ID NO:1 or encodes SEQ ID NO:2 or contains additional sequences in addition to SEQ ID NO:1.

Applicant's referral to the deposit of the cDNA on page 80-81 of the specification is an insufficient assurance that the required deposit has been made and all the conditions of 37 CFR 1.801-1.809 met.

If the deposit is made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit has been accepted by an International Depository Authority under the provisions of the Budapest Treaty and that all restrictions upon public access to the deposited material will be irrevocably removed upon the grant of a patent on this application. This requirement is necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State.

If the deposit is not made under the provisions of the Budapest Treaty, then in order to certify that the deposits comply with the criteria set forth in 37 CFR 1.801-1.809 regarding availability and permanency of deposits, assurance of compliance is required. Such assurance may be in the form of an affidavit or declaration by applicants or assignees or in the form of a statement by an attorney of record who has the authority and control over the conditions of deposit over his or her signature and registration number averring:

(a) during the pendency of this application, access to the deposits will be afforded to the Commissioner upon request:

(b) all restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application:

(c) the deposits will be maintained in a public depository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest; and

(d) the deposits will be replaced if they should become nonviable or non-replicable.

If a deposit is made after the effective filing date of the application for patent in the United States, a verified statement is required from a person in a position to corroborate that the biological material described in the specification as filed is the same as that deposited in the depository, stating that the deposited material is identical to the biological material described in the specification and was in the applicant's possession at the time the application was filed.

Applicant's attention is directed to In re Lundak, 773 F.2d. 1216, 227 USPQ 90 (CAFC 1985) and 37 CFR 1.801-1.809 for further information concerning deposit practice.

12. Claims 39-43, 50-51 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is undue include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

The claims are drawn to a polypeptides having at least 80-99% amino acid sequence identity to the polypeptide of SEQ ID NO:2 or the extracellular domain thereof. There is no functional limitation in the claims as far as to the polypeptide. Applicants have taught the polypeptide consisting of SEQ ID NO:2, as well as the transmembrane domains , see Figure 2). This polypeptide is not disclosed as having any function or activity and the specification does not teach an activity for the polypeptide or any active regions of the polypeptide. Thus one would not know if the polypeptide with the claimed homology would function as a polypeptide of SEQ ID NO:2.

The claim encompasses an unreasonable number of inoperative polypeptides, which the skilled artisan would not know how to use the claimed polypeptide.

There are no working examples of polypeptides less than 100% identical to the polypeptide SEQ ID NO:2 or the mature form thereof. The skilled artisan would not know how to use non-identical polypeptides on the basis of teachings in the prior art or specification. Even if the claimed polypeptides had a function, the specification does not provide guidance for using polypeptides related to (*i.e.*, 80%-99% identity) but not identical to SEQ ID NO:2. The claims are broad because they do not require the claimed polypeptide to be identical to the disclosed sequence and because the claims have no functional limitation.

It is well known in the art that even a single modification or substitution in a protein sequence can alter the proteins function. Protein chemistry is probably one of the most unpredictable areas of biotechnology. For example, the replacement of a

Art Unit: 1642

single lysine at position 118 of the acidic fibroblast growth factor by a glutamic acid led to a substantial loss of heparin binding, receptor binding, and biological activity of the protein (see Burgess et al, Journal of Cell Biology Vol 111 November 1990 2129-2138). In transforming growth factor alpha, replacement of aspartic acid at position 47 with asparagine, did not affect biological activity while the replacement with serine or glutamic acid sharply reduced the biological activity of the mitogen (see Lazar et al Molecular and Cellular Biology Mar 1988 Vol 8 No 3 1247-1252). Replacement of the histidine at position 10 of the B-chain of human insulin with aspartic acid converts the molecule into a superagonist with 5 times the activity of nature human insulin. Schwartz et al, Proc Natl Acad Sci USA Vol 84:6408-6411 (1987). Removal of the amino terminal histidine of glucagon substantially decreases the ability of the molecule to bind to its receptor and activate adenylate cyclase. Lin et al Biochemistry USA Vol 14:1559-1563 (1975).

These references demonstrate that even a single amino acid substitution or what appears to be an inconsequential chemical modification, will often dramatically affect the biological activity of the protein.

The claims are also broadly drawn to SEQ ID NO:2 or polypeptides that are 80-99% identical to SEQ ID NO:2. The specification teaches that the DNA encoding SEQ ID NO:2 is overexpressed in tumor vs. normal rectum, however, the specification does not teach that the polypeptide is over expressed in any tumor vs. normal tissue.

Those of skill in the art recognize that expression of mRNA, does not necessarily correlate nor predict equivalent levels of polypeptide expression. In fact, evidence

abounds in which protein levels do not correlate with steady-state mRNA levels or alterations in mRNA levels. For example, Fu et al (EMBO Journal, 1996, Vol. 15, pp. 4392-4401) teach that levels of p53 protein expression do not correlate with levels of p53 mRNA levels in blast cells taken from patients with acute myelogenous leukemia, said patients being without mutations in the p53 gene. Further, Powell et al (Pharmacogenesis, 1998, Vol. 8, pp. 411-421, abstract) teach that mRNA levels for cytochrome P450 E1 did not correlate with the level of corresponding protein, and conclude that the regulation of said protein is highly complex. Vallejo et al (Biochimie, 2000, vol. 82, pp. 1129-1133, abstract) teach that no correlation was found between NRF-2 mRNA and protein levels suggesting post-transcriptional regulation of NRF-2 protein levels. These references serve to demonstrate that the analysis of levels of polynucleotide transcripts cannot be relied upon to anticipate levels of protein expression. Further, Jang et al (Clinical and Experimental Metastasis, 1997, vol. 15, pp. 469-483, abstract) teach that further studies are necessary to determine if changes in protein levels track with changes in mRNA levels for metastasis associated genes in murine tumor cells, thus providing further evidence that one of skill in the art cannot anticipate that the level of a specific mRNA expressed by a cell will be paralleled at the protein level due to complex homeostatic factors controlling translation and post-translational modification. In addition, Pennica et al (PNAS 95:14717-14722, 1998) provides an example where the copy number is amplified but the RNA expression is actually reduced. Thus, the predictability of protein translation and its possible utility as

a diagnostic are not necessarily contingent on the levels of mRNA expression due to the multitude of homeostatic factors affecting transcription and translation.

Therefore, absent evidence of the protein's expression including the correlation to a diseased state, one of skill in the art would be unable to predictably use the polypeptides in any diagnostic setting without undue experimentation.

In view of the lack of guidance, lack of examples, and lack of predictability associated with regard to producing and using the myriad of derivatives encompassed in the scope of the claims, one skilled in the art would be forced into undue experimentation in order to practice the broadly claimed invention.

Priority

13. The examiner acknowledges the priority statement filed 7/16/02, however, because the claimed subject matter does not have a substantial asserted utility or a well established utility, the priority date of the claims are given the filing date of the instant application, 12/6/01. It is also noted that if applicant can overcome the utility rejection above, this application would then be granted the priority date of 8/24/01 which is to PCT/US00/23328 due to the priority map sent to the PTO which states that this application claims benefit to 60/096012, PCT/US99/12252, 09/380137, PCT/US00/23328. Application 09/380137 was unavailable for inspection and 60/096012 and PCT/US99/12252 do not disclose the polynucleotide is over expressed in tumor, thus there is no asserted utility for detection in tumor.

Claim Rejections - 35 USC § 102

14. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

15. Claims 39-45, 47, 50-51 are rejected under 35 U.S.C. 102(b) as being anticipated by Feng et al (WO 99/24836, published 5/99). This rejection is being made due to the priority art and is consistent with the enablement because for a 102 rejection the art must teach how to make.

The claims recite an isolated polypeptide having at least 80% amino acid sequence identity to a polypeptide of SEQ ID NO:2 and fused to an epitope tag.

Feng et al teach a polypeptide that is 100% identical to SEQ ID NO:2 (see the attached sequence alignment on the back of this Office Action) and the polypeptide can be fused to an epitope tag (see page 211).

16. Claims 39-51 are rejected under 35 U.S.C. 102(b) as being anticipated by Baker et al (WO 99/63088, published 12/99). This rejection is being made due to the priority art and is consistent with the enablement because for a 102 rejection the art must teach how to make.

Art Unit: 1642

Claims 39-45, 47, 50-51 have been described supra. Claims 46, 48-49 recite wherein the polypeptide comprises the extracellular domain lacking its signal sequence, the polypeptide encoded by the cDNA of ATCC 203099, a chimeric polypeptide comprising an epitope tag or an Fc region of an immunoglobulin.

Wood et al teach SEQ ID NO:2 and the sequence lacking its signal sequence and the polypeptide is encoded by the cDNA of ATCC 203099 and the polypeptide can have a epitope tag or an Fc region (see page 50, Figure 15 and page 310)

Conclusion

17. No claim is allowed.

18. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Larry R. Helms, Ph.D, whose telephone number is (703) 306-5879. The examiner can normally be reached on Monday through Friday from 7:00 am to 4:30 pm, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

19. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in


Art Unit: 1642

Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 308-4242.

Respectfully,

Larry R. Helms Ph.D.

703-306-5879



LARRY R. HELMS, PH.D.
PRIMARY EXAMINER